Please login to the form below

Not currently logged in

Pharma appointments, July 2012

Recent high-profile moves in the pharmaceutical and healthcare industries

 Philip Blake, Bayer


Bayer has named current US head of Bayer Healthcare Pharmaceuticals Philip Blake as its senior Bayer representative for the US.

Maintaining his current position in the US speciality pharma division of the company, Blake will also assume the role of Bayer Healthcare representative for the US on July 1, 2012.

It is common practice at the company to assign the role of senior Bayer representative for the US to a senior executive who already holds a significant business role within the region.

Blake, who has been with Bayer for more than 30 years, takes over from Greg Babe who is due to retire.

Shire has made two senior promotions, appointing David Colpman to lead its global business development team and elevating Ann Judge to its leadership team.

Colpman will take over from Barbara Deptula, who is retiring after eight years at the helm of the Dublin-based biopharmaceutical company's business development team.

He has been with Shire for over 12 years, leading many of its significant deals, and before that worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles.

Colpman began his industry career at ICI (now AstraZeneca) in formulation and manufacturing, and in his new role will report to Shire's chief executive Angus Russell.

Shire has also appointed Ann Judge, currently senior vice president of its global Human Resources team, to the Shire leadership team.

Judge has over 20 years of global HR experience in the pharmaceutical, chemical, and oil and gas industries, having begun her career with Dow Chemical. She joined Shire to lead its global HR team in late 2010, after spending six years with Wyeth Pharmaceuticals (now part of Pfizer).

David Colpman, ShireAnn Judge, Shire

Paul Laikind, ViaCyte

Paul Laikind has been named CEO of ViaCyte, a US biotech whose research focus is the use of stem cells to treat diabetes.

He replaces acting CEO Dr Allan Robins, who will continue to serve at ViaCyte as VP and chief technology officer.

Dr Laikind has spent over 25 years in the biotech and life sciences industry, and most recently served as chief business officer and senior VP of business development at the Sanford-Burnham Medical Research Institute.

The UK's BioIndustry Association (BIA) has named the director of public affairs firm APCO Steven Bates as its new CEO.

He replaces Glyn Edwards, who has the led the bioscience trade body on an interim basis since November, 2011.

Bates had only been in his present role at APCO since the beginning of the year, having previously served at Genzyme as its senior director external affairs and market access, Commonwealth and Ireland from March 2010 to January 2012.

During this time, he worked on the establishment of the government's Office for Life Science and was a member of the BIA's Communications Advisory Committee.

He initially joined biotech firm Genzyme in 2008 to serve as government relations director for the UK and Ireland.

 Steven Bates, BIA

Colin White, Penn Pharma

Penn Pharma has appointed Peter Goold and Colin White to senior positions in its supply chain team.

Peter Goold will take on the newly-created role of director of supply chain and project management at the UK-based pharma services company, while Colin White has been appointed as head of manufacturing, running the production operation at Penn's UK facility.

The Care Quality Commission (CQC), which regulates and inspects health and social care services in England, has appointed David Behan as its new chief executive.

In July, Behan will replace the CQC's only previous chief executive Cynthia Bower who announced in February, 2012, she would be resigning from the post after four years in charge.

Bower endured a troubled period in office, with her appointment being called into question over her handling of high mortality rates at the Mid Staffordshire NHS Foundation Trust, which was part of the NHS West Midlands strategic health authority (SHA) where she was chief executive prior to her time at the CQC.

David Behan, CQC

Israel Makov, Sun Pharma

Israel Makov, former president and CEO of Teva Pharmaceutical, has been appointed chair of the board of directors at Sun Pharma.

He takes over from Dilip Shanghvi who will remain managing director of the Indian generics firm.
Makov was president and CEO at Israel-based Teva from 2002 to 2007 having joined as VP for business development in 1995. He then served as executive VP from 1999 and then chief operating officer from 2001 to 2002.

The World Health Assembly has appointed Dr Margaret Chan as director general of the World Health Organization (WHO) for a second term, extending her role to June 30, 2017.

She has been in the position since 2006, and faced an eventful first term heading the UN agency to improve public health during both the avian influenza outbreak and the swine flu pandemic of 2009.

The latter incident led to Dr Chan and the WHO coming under fire from critics who claimed they had received advice from an influenza expert receiving payments from Tamiflu makers Roche and overstated the potential impact of the H1N1 virus.

At the time, Dr Chan argued that “decisions to raise the level of pandemic alert were based on clearly defined virological and epidemiological criteria”.

In her acceptance speech for her second term in office she said the biggest challenge for the WHO during the next five years will be to maintain both the financial and practical interest in better global health that has been seen in the early part of the 21st century.

Dr Margaret Chan, WHO

Dr Mark Porter, BMA

The British Medical Association (BMA) has voted in Dr Mark Porter as its new chair, replacing Dr Hamish Meldrum.
Dr Porter started his new position during a turbulent time for doctors in the UK. He took office shortly after the BMA implemented a day of strike action to oppose the coalition government's plans to change doctors' pensions so they contribute more and work for longer.

UK-headquartered life sciences recruitment company RSA has appointed Kristian Juergensen as managing director of RSA Germany.

Juergensen first joined RSA in 2006 as an executive search consultant, rising to director of RSA Interims in Germany before moving to a German generics company as head of tender management.

In his new role Juergensen will report to RSA's EMEA head John Callagher, who said he looked forward to seeing the company's German office develop and grow.

Meanwhile, RSA has recently moved its Swiss operations from Zug to offices at Dufourstrasse 25, CH-4052, Basel.

Kristian Juergensen, RSA

Julia Straker, PAN Advertising

Pan Advertising has appointed Julia Straker as head of strategic planning.

She joins the Richmond, UK-based agency from TBWA\Paling Walters, where she worked as a planner and was an integral member of its account and creative teams.

Merck KGaA has announced several senior US appointments at its EMD Serono division.

These include the selection of AstraZeneca's Evan Lippman as senior VP of neurodegenerative diseases and rheumatology and the internal promotion of Allene Diaz to the newly-created role of senior VP, head of US oncology.

The remaining changes are Rami Levin's promotion to VP of marketing, neurodegenerative diseases and rheumatology, and confirmation that Craig Millan will be senior VP and head of EMD Serono's US fertility, metabolic endocrinology and HIV franchise, a role he previously held on a temporary basis.

Lippman joins EMD Serono from AstraZeneca (AZ) where he most recently served as executive director of Crestor.
Previously, he held several senior roles at AZ including executive director and head of US business development, and also spent time at Pfizer.

Diaz has been involved in EMD's oncology business in the US since 2008, serving as VP oncology marketing. In addition, she also held the role of acting head, oncology global strategic planning from July 2010 to May 2011. Prior to that she held senior roles at Amylin Pharmacueticals, Biogen Idec and Pfizer.

Levin has spent nearly 15 years at Merck, and most recently served as chair and managing director of Merck AB in Sweden and Iceland. In his new role, he will report directly to Lippman.

Millan has been serving in his newly-confirmed position on an 'ad-interim' basis since earlier this year. Prior to this, he was EMD Serono's VP of endocrinology marketing, leading marketing efforts across reproductive health, growth hormone deficiency and HIV-related metabolic disorders.

Before joining Merck, Millan served as VP, commercial at Vertex Pharmaceuticals, and has previous experience in marketing roles at Pfizer.

Evan Lippman, Allene Diaz, Rami Levin, Craig Millan

Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron. Placet had served as chief financial officer at the French clinical stage pharma company since 2004, and takes up her new role immediately.According to Trophos, the promotion is part of an internal succession plan designed to provide continuity for the company as it looks to conclude ongoing development programmes and find partnerships for its advance clinical development drug candidates.

The European Medicines Agency (EMA) has appointed Merck Serono's Enrica Alteri as its new head of safety and efficacy of medicines. In her new position she will play a leading role in the application of the EMA's new pharmacovigilance legislation, which introduces new rules governing the monitoring, identification and assessment of adverse events caused by drugs. Dr Alteri was most recently head of risk management and epidemiology at Merck Serono's soon to be closed Swiss headquarters in Geneva, and takes over from Francesco Pignatti, the EMA's head of oncology. Pignatti had been acting head of safety and efficacy of medicines since March, 2012, following the departure of Xavier Luria. Dr Alteri has many years of experience in drug safety having served as director of pharmacovigilance at Serono, before its acquisition by Merck KGaA. She has also spent time working in medical safety teams at both Novartis and Ciba, and was involved in developing the safety profiles of such products as Coartem/Riamet, which is the World Health Organization's (WHO) recommended first-line treatment against malaria. She has also previously served as a member of the European Course of Pharmaceutical Medicine faculty (ECPM) in Basel, Swtizerland, and was part of the Council for International Organizations of Medical Sciences (CIOMS) working group on pharmacovigilance in resource-poor countries.

Nicola Redfern has been appointed director of market access at Celgene for the UK and Ireland. Redfern joins Celgene from Novartis where she was director of communications and external affairs for the Swiss pharma firm's oncology business unit. At Novartis, she was responsible for health economics and outcomes research, communications, patient advocacy, government affairs and leadership of the field-based NHS development team, and will fill a similar role at Celgene focusing on the changing NHS landscape.

US-based Antares Pharma has appointed Dr Jonathan Jaffe as its new VP of clinical development to head the company's progress in self-injection products and topical gel-based medicines. Dr Jaffe has over 20 years industry and academic experience, during which time he has led global clinical development programmes and conducted all phases of research, for respiratory, transplant and autoimmune indications at Schering Plough Research Institute, Novartis, and Forest Research Institute.
His most recent role was as a consultant in clinical programmes for Pharmanet-i3.

Professor Jonathan Montgomery has been appointed the first chair of the UK's newly launched Health Research Authority (HRA). Prof Montgomery will leave his current role as chair of Hampshire Primary Care Trust to head the government organisation set up in December, 2011, to protect and promote the interests of patients and the public in health research. Incorporating the National Research Ethics Service (NRES), it will work closely with organisations such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health Research (NIHR) to create a consistent national system of research governance. Eventually, it will also perform the Health Secretary's function of approving the processing of patient information for medical research. In addition to serving as chair of the HRA, Prof Montgomery will retain his roles as professor of healthcare law at the University of Southampton and chair of the Nuffield Council on Bioethics.

Pfizer has appointed Aijaz Tobaccowalla to lead its Mumbai-headquartered Indian operations, taking over from Kewal Handa who will retire in August. Tobaccowalla has more than 20 years' experience in the pharma industry, almost all of them spent at either Pfizer or Wyeth, which Pfizer acquired in 2009. He joined Wyeth in 1991 and held a number of business technology positions before joining leadership teams within Pfizer. In 2009 Tobaccowalla was appointed to his present role to lead the company's business technology function for all of its biopharmaceutical business units.

The UK's Medical Research Council (MRC) has appointed three new council members, including Dr Ruth McKernan, senior VP and chief scientific officer of Pfizer's Neusentis unit, and Dr Menelas Pangalos, executive VP of innovative medicines at AstraZeneca (AZ). The third new addition is Baroness Onora O'Neill, a member of the House of Lords who has been appointed as an expert lay member. From October 1, 2012, each will serve an initial term of four years on the council of the MRC, a publicly-funded body that aims to support medical research across the UK. Dr McKernan has been with Pfizer since 2005, serving in positions such as VP of biology at its plant in Sandwich, Kent; head of the company's research technology centre in Boston, US; and VP for external research in Europe. Prior to her time at Pfizer, Dr McKernan spent 17 years at Merck & Co, eventually becoming the head of its neuroscience research centre in Harlow, UK. Dr Pangalos has been in his position at AZ since 2010, having previously held the role of senior VP and chief scientific officer of neuroscience research at Pfizer and senior VP of research at Wyeth.

Bob Harrell, former director of integrated marketing at Shire Pharmaceuticals, has joined the cloud-based software company Appature as VP marketing, healthcare.
He will lead marketing efforts in the pharma and medical device fields for Appature as it looks to support healthcare marketers' efforts in data mining, campaign launches and gaining insights to develop customer relationships.

The director of research charity the Wellcome Trust Sir Mark Walport has been appointed chief scientific adviser to the UK government. Taking up his new post in April, 2013, Sir Mark will replace Sir John Beddington in providing advice directly to Prime Minister David Cameron and the cabinet concerning scientific issues.

Fraser Black has been appointed as managing director at BioCity Scotland – a life sciences hub based at a former MSD facility in central Scotland. He joins from GE Life Sciences where he was global services solutions director, and takes over from Ian Webster who had been managing director at BioCity Scotland since its launch in January, 2012.


Related links

FAQ: How do I get my move listed


Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...